ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Astellas Announces Approval in Japan for the treatment of prostate cancer, Gonax for partial changes
January 09, 2019Gonax® is a GnRH receptor antagonist with a subcutaneously injectable formulation. Astellas acquired exclusive development and commercialization rights of Gonax® for the use of prostate cancer treatment in Japan from Ferring Pharmaceuticals in January 200 -
Astellas Announces Approval in Japan for the treatment of prostate cancer, Gonax for partial changes
January 09, 2019Gonax® is a GnRH receptor antagonist with a subcutaneously injectable formulation. Astellas acquired exclusive development and commercialization rights of Gonax® for the use of prostate cancer treatment in Japan from Ferring Pharmaceuticals in January 200
Pharma Sources Insight January 2025
